Cipla said that its US business will see one launch per quarter for at least four quarters starting from Q4.
“We will start seeing one launch per quarter starting mid to end of Q4. Then we will probably see this for about 3 or 4 quarters and hopefully sustainably after that,” said Umang Vohra, MD and Global CEO of the company.
In the second quarter, Cipla saw a good recovery from the first quarter.
Elaborating on the numbers, Vohra said the trade generic segment has recovered and grew 60 percent and the branded Rx prescription business grew by 13 percent.
Detailing the likely third-quarter performance and outlook going forward, he said, “The generic market should resume its growth trajectory in Q3. So we are actually looking at Q3 and Q4 to be back to growth… on the branded side, I think we are pretty clear that we are looking at roughly double-digit growth for the balance half of the year.”
When asked about the average sales the company would be able to generate in coming quarters, Vohra said, “We are not guiding to the exact nature of what dollar value, etc. but we are looking at growth over the last year in Q3 and Q4.”